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Background: The impact of pre-pregnancy pulmonary and nutritional status in pregnancy outcomes of women with cystic fibrosis (CF) is
not clearly defined.
Methods: A chart review of CF women who attended the University of Washington Medical Center (UWMC), Seattle WA. from January
1989 until May 2004.
Results: There were 43 pregnancies resulting in 36 live births among 25 of 189 CF women. In the subset of CF women receiving their
obstetric care at the UWMC whose FEV1 was <50% predicted, infant weight was lower than in women with a higher FEV1 (2.9 kgT0.4
(range 2.2–3.3 kg) versus 3.4T0.8 kg (range 2.5–5.1 kg)) p =0.05 although the gestational ages were the same (37T2 weeks (range 33–
39 weeks) versus to 38T2 weeks (range 35–40 weeks) p =0.17). Infant weight and gestational age of women whose initial BMI was <20 kg/
m2 was no different from women with a normal initial BMI (3.0T0.4 kg, range 2.2–3.4 kg versus 3.3T0.8 kg, range 2.6–5.1 kg p =0.29, and
37.7T2.4 weeks, range 33–39 weeks versus 37.2T2.1 weeks, range 34–40 weeks).
Conclusions: CF women with severe pulmonary impairment tend to have lower weight babies but it remains difficult to determine
prospectively which CF women will tolerate pregnancy well. Aggressive antepartum management is recommended for all CF women.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pregnancy; TPN; Nutrition; CFRDM; Pulmonary function1. Introduction
Women with CF usually conceive relatively easily
despite delayed puberty and theoretical problems of altered
cervical mucus leading to impaired sperm penetration [1,2].
Although there have been recent advances in the
management of CF with aggressive antibiotic regimens,
improved airway clearance techniques and greater attention
to nutritional needs with a multi-disciplinary approach, CF
still leads to premature death [3]. The median age of death
in patients with CF in the U.S. was 8.4 years in 1969 and
in 2004 was 35 years (Cystic Fibrosis Foundation’s Patient1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.01.002
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E-mail address: moira@u.washington.edu (M.L. Aitken).Registry (CFFPR)). The CFFPR has reported approximately
140 pregnancies annually in CF women since 1991. This
projects that 3–4% CF women will become pregnant each
year.
The first successful pregnancy in a woman with CF was
reported in 1960 [4]. She died six weeks after delivery.
Currently, epidemiological information both from a large
single center and nationally from throughout the U.S. has
shown that the long term outcome of women with CF who
become pregnant is not worse than CF women who do not
become pregnant [5,6]. However, the health status of CF
women during pregnancy has not been well described [7].
Specifically, the anticipated weight gain of pregnancy in a
cohort of pancreatic insufficient and diabetic women is
unclear. Neither is there much detailed information on the
potential impact of pregnancy on pulmonary function given
the mechanical restriction of the growing uterus on thes 5 (2006) 85 – 91ed by Elsevier B.V. All rights reserved.
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Fig. 1. The reproductive histories of 189 women with CF attending the
UWMC. TOP = termination of pregnancy. SAB = Spontaneous abortion.
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women whose airways are chronically infected with S.
aureus and P. aeruginosa. There are even less details about
the effects of CF on intrapartum events and postpartum
recovery. Therefore, we performed a chart review of
prospectively collected clinical information to evaluate the
effect of CF on pregnancy, its management, and outcome
over a 15-year period in pregnancies in CF women at the
University of Washington Medical Center (UWMC), Seattle.Table 1
Demographic information of the 16 women with cystic fibrosis who
received their obstetric care at the UWMC
Factor MeanTSD, median (range)
Age (years) 24T4, 22.5 (16–29)
BMI (body weight [kg] /height [m2]) 22.1T4.3, 21.2 (17.7–34.9)
Number with BMI20 7 /16
Lung function
FEV1 % predicted 61T22%, 56% (33–99%)
FEV1 40–50% predicted 3 /16
FEV1<40% predicted 4 /16
Number with severe
CF mutations (Class 1, 2, 3)
14 /16
Number with pancreatic insufficiency 15 /16
Number with CF-related diabetes 5 /16
Sputum microbiology
Number with S. aureus 3 /16
Number with P. aeruginosa 6 /16
Number with P. aeruginosa +S. aureus 6 /16
Number with P. aeruginosa +B. cepacia 1 /16
FEV1=Forced expiratory volume in 1 s.2. Materials and methods
The UWMC is the site of the Adult Program of the
Cystic Fibrosis Foundation Accredited CF Center that has
provided care to adults with CF in the Pacific Northwest
since January 1989. A mandate of accreditation is that
centers provide multi-disciplinary care for their patients.
Centers are staffed by physicians, clinical nurse specialists,
nutritionists, respiratory therapists and social workers.
Consultations and management for other issues are provided
by subspecialists including gastroenterologists, endocrinol-
ogists and perinatalogists within the medical center.
A retrospective chart review was conducted on all CF
women at UWMC who had been pregnant at any time
between January 1989 and May 2004. Approval for this
study was obtained from the UW Institutional Review
Board. Clinical information obtained included age, race, CF
genotype, presence of pancreatic insufficiency (defined as
requiring pancreatic enzymes), pre-existing cystic fibrosis
related diabetes mellitus or glucose intolerance (as defined
by a random blood glucose >125 mg/dl or hemoglobin
A1C>6% prior to pregnancy) and sputum microbiology.
Throughout pregnancy and postpartum, maternal weights,
changing diabetic status and pulmonary function were
recorded. The number of antenatal visits, the number of
hospital days and the number of days that patients receivedin-patient intravenous antibiotics antepartum and postpar-
tum were recorded. Intrapartum events and outcomes
included gestational age at delivery, mode of delivery, birth
weight, and intrapartum obstetrical complications were
collected. Postpartum length of stay and neonatal compli-
cations including CF were recorded.
2.1. Statistical analysis
This is a descriptive study of a retrospective chart review
from a single tertiary care center. Clinical data are expressed
as mean, median and range. The data was examined using
each patient rather than each pregnancy, as the latter method
leads to a bias toward patients with multiple births. Detailed
statistical data was performed on the subset of patients
receiving their obstetric care at the UWMC and was
analyzed using an unpaired student t-test and chi square
statistic where appropriate. Spearman correlation coeffi-
cients were used.3. Results
3.1. Characteristics of all CF women with pregnancies
189 women with CF received care at the UWMC during
the 15-year period (Fig. 1). All women were Caucasian.
During the study years, 25 women had pregnancies resulting
in 36 live births, 3 first trimester elective terminations, and 4
first trimester miscarriages (Fig. 1). One of the 25 women,
an 18 year old waiting bilateral lung transplantation
underwent a medically recommended termination in the
first trimester. At the time of termination, her forced
expiratory volume in one second (FEV1) was 16%
predicted, her arterial blood gases were: pH 7.46, pCO2
Table 2
Antepartum, intrapartum and postpartum information of UWMC women
Factor MeanTSD, median
(range)
Antepartum
(n =15)
Prenatal visits 12.4T5 (6–22)
Gestational age at
entry into care (wks)
11.3T8, 8 (6–37)
Number of hospital days:
all 15 patients
19T21, 10 (3–71)
Number of women
with 4 hospital days
4 /15 women
Number of acute
pulmonary
exacerbations/patient
2T2, 2 (0–5)
Days on antibiotics
IV 30T40, 11 (0–143)
Oral 8T12, 4 (0–42)
TPN required 6 /15
Weight gain (kg)
All 15 patients 10.4T4.5 (1.8–21.4)
TPN 8.2T3.6
No TPN 12.3T4.5
Pregnancy-related
DM (no TPN pts)
A1 = 3, A2 = 2, B = 1
Intrapartum and
postpartum
(n =16)
Delivery route
Vaginal 13
Induction 11: 9=nutritional/
pulmonary
1=oligohydramnios
1=PPROM
Cesarean 3: 1=breech+
oligohydram
1=33 wk-placental
abrupt
1=active HSV
Postpartum length of stay
(days): all 16 patients
6T8 days (1–28)
Vaginal delivery 4.5T7 days (1–28)
Cesarean section 8T7 days (4–16)
Gestational age at
delivery (all 16 pts)
37T2 wks (33–39)
37 weeks 9 /16
33–36 6 /7 weeks 7 /16
Birthweight (g)
37 weeks 3410T536 (2748–4337)
33–36 6 /7 weeks 2669T258 (2211–2948)
Birth defects 0
Cystic fibrosis 0
Information is only available on 15 /16 women as one patient was
diagnosed and delivered on the same day at 37 weeks gestation.
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Fig. 2. Pulmonary function (FEV1 %) of CF women during pregnancy.
Pulmonary function did not change during pregnancy.
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tation. She died of respiratory failure eight months
following termination of pregnancy. We chose not to include
her demographic data as she never had a live birth.
Of the 24 women in the study, one woman had two
terminations of pregnancy for social reasons and three other
women had a total of four first trimester miscarriages. The
age of the 24 women at the time of their first pregnancy that
produced a child was 24T5 years (median 23 years, range
16–30 years). Nineteen of these 24 women had severe CF
genotypes (class 1,2, or 3), one had a milder class 4 and four
had unknown CF genotypes.To date, 14 of 24 women have had one child, eight have
had two, and two have had three children (Fig. 1). The
preconception lung function in the women who had one
child tended to be lower than those who had more than one
child; the FEV1 % of predicted was 54T20 versus 80T15
( p =0.004), but there was no difference in the pre-conception
BMI 20.8 kg/m2T2.3 versus 23.7 kg/m2T5.6 ( p =0.23).
3.2. Comparison of CF women who received prenatal care
at UWMC versus elsewhere
Sixteen of the 24 women received their prenatal care at
UWMC. The UWMC CF women appear representative of all
pregnant women as the initial pulmonary function and BMI of
these two groups are the same although the UWMC women
tended to be a little younger 24T4 years (range 16–29)
compared to 28T4 years (range 20–34, p=0.06) in the
8 women who received their obstetrical care elsewhere.
3.3. Health of CF women receiving obstetric care at UWMC
at conception (Table 1, n =16)
The demographic information of the 16 women with CF
who received their obstetric care at the UW is shown in
Table 1. It should be noted that prior to pregnancy 7 /16 had
an FEV1 less than 50% predicted, 7 /16 had a BMI less than
20 kg/m2 and 5 /16 had CF related diabetes mellitus.
3.4. Antepartum experience of women with pregnancies
followed at UWMC (Table 2)
Antepartum, intrapartum and postpartum information of
UWMC women are summarized in Table 2. The number of
days of inhaled antibiotic treatment could not be accurately
determined. A lower FEV1 % predicted at the beginning of
E.Y. Cheng et al. / Journal of Cystic Fibrosis 5 (2006) 85–9188pregnancy was associated with more hospitalization days
(R =0.50) and more IV antibiotic days (R =0.61). However,
there was no clear evidence of change in lung function with
pregnancy (Fig. 2).
A lower preconception BMI was associated with more
hospital and IV antibiotic days (R =0.39 and 0.44, respec-
tively). The weight gain of the UWMC women was
10.4T4.5 kg (median 10.9, range 1.8–21.4, Fig. 3). The
weight gain of patientswho delivered at termwas 11.4T5.0 kg
(median 10.9, range 5.4–21.4).
Six women required total parenteral nutrition (TPN),
including a CF woman who was pancreatic sufficient with a
pre-pregnancy BMI of 27.1 kg/m2. The indication for the use
of TPN was inadequate weight gain or weight loss over
several weeks (n =5) and intractable nausea and vomiting
(n =1). Two/six patients had inadequate weight gain of 1.8 kg
in 8 weeks and 4.1 kg over 12 weeks. Three/six patients had
weight loss of 0.9 kg in 17 weeks, 1.4 kg over 30 weeks and
1.8 over 19 weeks. TPN was commenced at gestational week
17, 25, 27, 27, 29 and 30 (mean 26T5, range of 17–30
weeks) and TPN was delivered to the patients for 5, 7, 8, 9,11
and 16 weeks (mean 10T4, range 5–16 weeks). The daily
calories delivered were 1.2 to 1.3 the basal energy expendi-
ture. One liter of 50–70% dextrose with 10–15% amino
acids plus 250 cc of 10–20% lipids were given each 24 h. The
total daily calories in the TPN varied from 2175 to 3080 kcal.
TPN was delivered through permanent pre-existing in-
dwelling catheters in three patients, and a peripherally
inserted central catheter (PICC) line was inserted for this
purpose in the three other patients. One patient had an
elevation of liver function tests (LFTs) when on TPN. This
elevation in LFTs was due to the TPN rather than CF liverTPN
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Fig. 3. Weight gain in the ante and postpartum period of 14 /16 UWMC CF patients
in 2 /16 UWMC women. Weight gain in the non-TPN patients was greater than th
patients.disease, as she never had elevations in LFTs prior to or
following this unique episode, and her LFTs improved upon
reducing the TPN delivered. Her LFTs peaked with a
bilirubin of 2.1 mg/dl, alkaline phosphatase 275 U/l, alanine
aminotransferase of 339 U/l and aspartate aminotransferase
of 327 U/l.
The pre-pregnancy BMIs in the women who required
TPN were similar to those who did not require TPN, 21T3
and 23T5 kg/m2, respectively. The mean weight gain
during pregnancy was greater in those patients not
requiring TPN than in those requiring TPN (8.2 kgT3.6
compared to 12.3 kgT4.5, p =0.09, Fig. 3). There was no
difference in the pre-pregnancy lung function of women
who required TPN compared to those who did not.
Five of 16 women demonstrated glucose intolerance either
by an elevated random blood sugar or by an elevated
glycosylated hemoglobin prior to conception. One women
required insulin during her pregnancy. A second woman
required TPN which contained insulin in the formulation.
Five other women were diagnosed with pregnancy related
diabetes as defined by a serum glucose of >140mg/dl after an
oral glucose load of 50 g at 28 weeks gestation. One of these
women later required TPN and the other 4 were managed on
diet. The mean weight gain of the diabetic women was no
different from the non-diabetic women (11.2 kgT4.6, median
10.7 versus 9.0 kgT4.6, median 10.9, p =0.25).
3.5. Intrapartum and postpartum events and birth outcomes
(Table 2)
Thirteen of the 16 women delivered vaginally of which
11 were induced. The indications for induction wereNo TPN Postpartum
n (months) 
0 2 4 6 8 10 12
receiving or not receiving TPN. Detailed information could not be obtained
ose receiving TPN ( p =0.09). There was rapid weight loss postpartum in all
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(n =9), oligohydramnios (n =1) and preterm rupture of
membranes (n =1). Three women were delivered by
cesarean section; for breech presentation and oligohydram-
nios (n =1), acute placental abruption at 33 weeks gestation
(n =1), and active HSV lesions at the time of labor at term
(n =1). There were no intrapartum or postpartum obstetrical
complications.
The longer postpartum length of stay for both vaginal
(4.5 daysT7) and cesarean (8 daysT7) deliveries were all
related to maternal pulmonary and/or nutritional decompen-
sation. All of the women were at pre-pregnancy weight
within two months after delivery (Fig. 3). All of the women
except one, attempted breastfeeding, and all but one stopped
within 3 months because of weight loss and lack of time.
There was one maternal death on postpartum day 28. Her
conception FEV1 was 37% of predicted and her conception
BMI was 17.7 kg/m2. She was hospitalized for 61 days
during her pregnancy because lack of weight gain, recurrent
pulmonary exacerbations, and poor social support at home.
She required TPN, gained 9.5 kg during the pregnancy, and
was induced and successfully delivered at 36 weeks
gestation. She was clinically depressed throughout pregnan-
cy and postpartum, and her depression was treated with
counseling and anti-depressant medications. She declined
medical therapy including chest physical therapy and died
of respiratory failure 28 days after delivery.
The mean gestational age at delivery for all 16 women
was 37 weeksT2. There were 7 infants delivered between
33 weeks and 36 6 /7 weeks gestation (36% prematurity
rate). Three of these deliveries, at 33 weeks, 34.5, and
35 weeks gestation occurred in women who were on TPN.
There were no deliveries less than 33 weeks gestation. The
birth weights for all of the infants were appropriate for
gestational age. There were no unusual neonatal complica-
tions, birth defects, or infants affected with CF.
The infants of the glucose intolerant mothers tended to be
heavier than those with normal glucose tolerance (3261 gT
888 versus 2998 gT268, p=0.25).
Seven of 16 UWMC CF women had an initial FEV1 less
than 50% predicted. The mean gestation age of these
women’s pregnancies was 37T2 weeks (range 33 weeks and
2 days to 39 weeks) compared to 38T2 weeks (range 35
weeks to 40 weeks; p =0.17) in women whose FEV1 was
greater than 50% predicted. The mean weight of these two
infant groups were 2.9T0.4 (range 2.2–3.3 kg) versus
3.4T0.8 kg (range 2.5–5.1 kg; p =0.05 ).
Seven of 16 UWMC CF women had an initial BMI of
less than 20 kg/m2. The mean gestation age of these
women’s pregnancies was no different from CF women who
had a normal initial BMI (meanTSD 37.7T2.4 weeks, range
33–39 weeks versus 37.2T2.1 weeks, range 34–40 weeks).
The mean weight of these two infant groups was 3.0T0.4 kg,
range 2.2–3.4 kg versus 3.3T0.8 kg, range 2.6–5.1 kg
( p =0.29). Six/sixteen women had both and FEV1 less
than 50% predicted and a BMI less than 20 kg/m2. Evenin this extremely sick group, the gestational age was
37.5T2.5 weeks (range 33–39 weeks) and fetal weight
was 2.9T0.4 kg, range 2.2–3.4 kg. There was a tendency
for the fetal weight to be lower in this pulmonary and
nutritionally impaired subset ( p =0.19). The diabetic
women were equally divided in women whose initial
BMI was greater or less than 20 kg/m2.4. Discussion
This is the largest review of detailed antepartum care in a
cohort of CF patients at a large tertiary care center in the
United States. The lung function and BMI of CF women
who chose to have obstetric care at the UWMC were the
same as women not choosing to have their obstetric care at
the referral center and thus are a representative CF
population of the Pacific Northwest. Although there have
been obstetric CF case series from France, Britain, Norway
and Sweden, Israel and Canada, there are no detailed case
series from the United States [8–13]. Moreover, these prior
obstetric series date back as far as 1963 when both obstetric
and CF care were markedly different from current clinical
practice. Our series is unique in that we have detailed
information regarding the antepartum care specifically
regarding pulmonary and nutritional issues in these women
and the medical resources required for good fetal outcome.
Half of adult CF patients in the U.S. are in nutritional
failure [3]. This nutritional failure is thought to be multi-
factorial. The large majority of CF patients have pancreatic
insufficiency and require treatment with pancreatic enzyme
supplementation. However, even with this treatment patients
suffer from malabsorption. There is loss of bile salts and bile
acids and there is decreased intake because of anorexia from
chronic disease, reflux and constipation. Finally there is
increased energy expenditure from chronic pulmonary
infections and increased work of breathing. Oral food
supplementation is often advised for CF patients. A small
minority of adult CF patients accept placement of a
percutaneous gastric (PEG) tube to facilitate weight gain
[14]. In the latter part of pregnancy, the expanding uterus
increases reflux and makes PEG feeding impractical.
Almost half of our patients were in nutritional failure at
the time of conception and thus are representative of the
U.S. CF population. The median weight gain of the patients
in our series (10.4 kg) was as high as any prior CF
population series (lowest in France, 5.7 kg and equally high
in Norway and Sweden, 10.4 kg) [6,8,10,11]. With
aggressive oral supplementation and with TPN in a third
of our patients, all delivered fetuses of appropriate weight
for gestational age. A novel finding of our study was the
very rapid weight loss of CF women after delivery. All
women had resumed their pre-pregnancy weight within two
months of delivery. This may reflect the lack of time that
these women have to maintain adequate caloric intake to
meet the metabolic demands of their chronic illness, the
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newborn.
Cystic fibrosis related diabetes mellitus (CFRDM) is
present in the large majority of adult CF patients. Indeed, in
a large study of this issue only 23% patients had a normal
glucose tolerance test at age 20 years [15]. Thus in our
series, we had less diabetic patients than might be
anticipated. CFRDM is different from type 1 diabetes; CF
patients make enough insulin to prevent ketogenesis, and a
relative glucagon deficiency also protects them from ketone
formation. CFRDM patients do not have the HLA-DR3 or
DR4 profiles of type 1 diabetes but 25% of the patients do
have antibodies to insulin. In our study, the presence of
CFRDM did not appear to negatively impact maternal or
fetal outcome.
The median survival of patients with CF is 35 years [3].
It is believed that CF patients lose 1.5–2% of their lung
function annually. Thus, the median lung function of our
population would predict that, our women who reproduce
would live longer than the average CF patient. Indeed
longer survival is observed in CF women who reproduce
than those who do not reproduce [5]. However, the
pulmonary function of our patients (median FEV1 of 56%)
was lower than in prior obstetric case series (61–76%
predicted) [6,8,10–12]. Unlike our case series, in these prior
studies only a small minority of patients had severe
pulmonary impairment (defined as less than 50% predicted
normal) [6,8,10,11,16]. Thus, with the increased survival of
CF patients, and improved obstetric care, CF women with
severe disease are choosing to reproduce.
Cardiac output increases in pregnancy, and it is
speculated that pulmonary artery pressures may rise in
patients with severe pulmonary impairment. ECHO cardio-
grams were not performed to examine pulmonary artery
pressures. However no patient developed physical signs of
overt right sided heart failure despite a large minority of
patients having severe pulmonary impairment.
The obstetric care of CF women is expensive. All of the
deliveries were uncomplicated. Yet the mean length of stay
for cesarean delivery (8 days) and vaginal delivery (4.5 days)
exceeds the generally accepted 3 days for cesarean deliveries
and 24 h for vaginal deliveries in a normal obstetric
population. All of our patients required antepartum
hospitalizations for pulmonary exacerbations or TPN, and
only four of our patients had antepartum hospital days of
less than 4 days. Our analysis did not include the number
of outpatient intravenous antibiotic days incurred by our
patients. One of our patients had 89 hospital days, some of
those in the intensive care unit. Our experience illustrates
that it is difficult to accurately predict uneventful
pregnancies. Therefore, patients should be counseled about
the possibility of hospitalization and the risk of incurring
substantial medical bills.
Cystic fibrosis remains a fatal disease. An issue that often
occurs is who is going to raise the children of CF women. If
a CF woman loses 1.5–2% of her lung function annually,the ‘‘average’’ CF woman in our series would be eligible for
bilateral lung transplantation 13–17 years after she has her
first child. Those with severe lung function are less likely to
be able to raise their children to adulthood and ideally
should plan guardianship of their children in the event of
their own early demise.
Our study has several important limitations. This is a
single center study although it is a tertiary referral center for
the Pacific Northwest. We have relatively small numbers of
patients and pregnancies so there are repeated type II errors
in our statistical comparisons. Thirdly, medical practice
evolved over the 16 years of the study. Although the
primary obstetric and medical care providers remained
constant, a more aggressive approach of increased antibiotic
use, hospitalizations and TPN was adopted over time.
Finally, the UWMC CF team may have not have been
informed of abortions or miscarriages of the women not
receiving obstetric care at the center. However, this
omission would not detract from our delivery information.
In conclusion, it remains difficult on an individual basis to
determine which CF women will tolerate pregnancy well and
which will not. However, the findings of this study may
provide general guidelines for the care of pregnancies in CF
women. Our patients entered prenatal care early and this
probably reflects the pre-pregnancy counseling by the multi-
disciplinary CF team and encouragement for our patients to
plan their pregnancies. Patients should be prepared for more
frequent pulmonary exacerbations or the need for TPN which
would require long term indwelling intravenous catheters,
hospitalizations, and home IV treatments. Our series revealed
that nutritional concerns do not end at the time of delivery.
And in fact, nutritional issues for the CF mother is probably
more important in the postpartum period when she is
particularly vulnerable because of lack of sleep and fatigue
in caring for a newborn. Thus, a CF expectant mother should
be counseled to arrange for support at home so that she has
time to eat and complete her own treatments in addition to
caring for her newborn. Our finding of such rapid weight loss
postpartum underscores the importance of frequent surveil-
lance of maternal health status in the immediate postpartum
period. We were aggressive in treating pulmonary exacer-
bations and inadequate weight gain in our patients, but our
series of patients was too small to conclude whether this
had any impact on the favorable pregnancy outcomes that
we experienced. There were no preterm deliveries less than
33 weeks and all infants were appropriately grown. The
only adverse event from aggressive IV antibiotics and TPN
was one patient with elevated LFTs due to the TPN. Five
of our patients met CFF criteria for glucose intolerance or
CFRDM. Yet the impact of CFRDM on pregnancy or vice
versa could not be clarified in our small series.
In summary, almost all CF women appear able to deliver
at 33 weeks gestation or later. Women with severe
pulmonary impairment tend to have lower weight babies.
The course of pregnancy cannot be predicted in any
individual patient and all CF women should anticipate
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